晚期子宫颈癌免疫治疗的现状  

Current Status of Immunotherapy for Advanced Cervical Cancer

作　　者：舒环通 耿海涛[1] 苏跃 李绵利[1] SHU Huantong;GENG Haitao;SU Yue;LI Mianli(Department of Oncology,Affiliated Hospital of Binzhou Medical College,Binzhou 256600,China;不详)

机构地区：[1]滨州医学院附属医院肿瘤科,山东滨州256600

出　　处：《中国医学创新》2025年第3期180-185,共6页Medical Innovation of China

摘　　要：子宫颈癌作为常见的妇科肿瘤之一,是临床现在所面临的一个严峻的考题,尤其是对于晚期的子宫颈癌,其治疗手段还比较局限。目前,晚期子宫颈癌的治疗除了标准的同步放化疗之外,免疫治疗现在也逐渐走向幕前,抗程序性细胞死亡蛋白-1(PD-1)是目前使用最广泛的免疫检查点抑制剂,现在有许多的PD-1抑制剂相继进入临床试验,其中大部分是研究PD-1抑制剂单药或联合其他药物治疗晚期子宫颈癌的效果。本综述介绍了一些已经比较成熟的及一些新兴的关于PD-1抑制剂的临床试验,主要是PD-1抑制剂单独使用、联合化疗药物使用及联合同步放化疗使用,通过总结这些临床试验的疗效可以更好地指导临床上对相关药物的熟练应用,为将来改善晚期子宫颈癌患者的疗效和生活质量提供帮助。As one of the common gynecological tumors,cervical cancer is a serious clinical problem,especially for advanced cervical cancer,its treatment is still relatively limited.At present,in addition to standard concurrent chemoradiotherapy,immunotherapy for advanced cervical cancer is also gradually moving to the tentorial stage.Anti-programmed cell death protein-1(PD-1)is the most widely used immune checkpoint inhibitor at present,and many PD-1 inhibitors have entered clinical trials successively.Most of these are studying the effects of PD-1 inhibitors alone or in combination with other drugs to treat advanced cervical cancer.This review introduces some mature and emerging clinical trials on PD-1 inhibitors,mainly the single use of PD-1 inhibitors,the use of combined chemotherapy drugs and the use of combined chemoradiotherapy.By summarizing the efficacy of these clinical trials,it can better guide the skillful application of related drugs in clinical practice.To help improve the efficacy and quality of life of patients with advanced cervical cancer in the future.

关 键 词：晚期子宫颈癌 免疫疗法 PD-1抑制剂 临床试验 

分 类 号：R737.33[医药卫生—肿瘤]